1. The FDA is planning a public meeting on July 18 to solicit input on generic drug approval standards and procedures. The effort, a part of the agency’s Drug Competition Action Plan, is designed to prevent the pharmaceutical industry from “gaming” its regulatory rules, said FDA commissioner Scott Gottlieb. (FDA Voice)

2. Mylan reportedly provided rebates to at least six state Medicaid programs with the stipulation that they would restrict access to competitors of its EpiPen auto-injector. (Stat)

3. Senate Republican leaders are expected to release a draft bill for the replacement of Obamacare today. A vote on the bill could take place as early as next week. (Reuters)

4. The state of Missouri is suing three drugmakers — Endo Pharmaceuticals, Purdue Pharma, and Janssen Pharmaceuticals — for allegedly distorting scientific evidence about addictive opioids. (AP)

5. A federal jury ruled that Teva Pharmaceutical Industries must pay GlaxoSmithKline more than $235 million for patent infringement related to the generic version of blood pressure treatment Coreq. (Reuters)